Login to Your Account



Gilead Halts Two Drugs For HIV, Reports 'Lighter' Third Quarter

By Randall Osborne


Monday, October 25, 2004
Largely on the strength of its HIV franchise, Gilead Sciences Inc. reported a 55 percent income hike for the third quarter, but the company said beginning work on two more potential drugs for the virus will be stopped because of experimental results that have been less than encouraging. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription